Gelteq (GELS) announced the appointment of Dr. Paul Wynne as its Chief Scientific Officer. Wynne will oversee the product and formulation strategies and the growth of Gelteq’s scientific team and various business verticals. He will assist with Gelteq’s intellectual property portfolio, academic partnerships, gel formulations, and distribution channels, and will work closely with manufacturing and supply side partners. Prior to joining Gelteq, he was the Manager of the Medicines Manufacturing Innovation Centre at Monash University in Melbourne for eight years.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GELS:
- Gelteq receives FDA approval of its suitability petition for new animal drug
- Gelteq announces largest U.S. customer increases initial order by 50%
- Gelteq announces 400,000 units enter production in November
- Opening Day: Heritage Distilling, Dynamix open for trading
- Gelteq appoints Bendell as President of U.S. Operations